CN105101970B - β-内酰胺酶抑制剂 - Google Patents

β-内酰胺酶抑制剂 Download PDF

Info

Publication number
CN105101970B
CN105101970B CN201480013394.2A CN201480013394A CN105101970B CN 105101970 B CN105101970 B CN 105101970B CN 201480013394 A CN201480013394 A CN 201480013394A CN 105101970 B CN105101970 B CN 105101970B
Authority
CN
China
Prior art keywords
optionally substituted
compound
acid
alkyl
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201480013394.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN105101970A (zh
Inventor
克里斯多佛·J·伯恩斯
丹尼斯·戴格尔
斌·刘
丹尼尔·麦加里
丹尼尔·C·佩维尔
罗伯特·E·李·特劳特
兰迪·W·杰克逊
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
VenatoRx Pharmaceuticals Inc
Original Assignee
VenatoRx Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by VenatoRx Pharmaceuticals Inc filed Critical VenatoRx Pharmaceuticals Inc
Publication of CN105101970A publication Critical patent/CN105101970A/zh
Application granted granted Critical
Publication of CN105101970B publication Critical patent/CN105101970B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201480013394.2A 2013-01-10 2014-01-10 β-内酰胺酶抑制剂 Expired - Fee Related CN105101970B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361751161P 2013-01-10 2013-01-10
US61/751,161 2013-01-10
US201361783261P 2013-03-14 2013-03-14
US61/783,261 2013-03-14
PCT/US2014/011144 WO2014110442A1 (en) 2013-01-10 2014-01-10 Beta-lactamase inhibitors

Publications (2)

Publication Number Publication Date
CN105101970A CN105101970A (zh) 2015-11-25
CN105101970B true CN105101970B (zh) 2018-11-20

Family

ID=51061422

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480013394.2A Expired - Fee Related CN105101970B (zh) 2013-01-10 2014-01-10 β-内酰胺酶抑制剂

Country Status (6)

Country Link
US (6) US9403850B2 (enExample)
EP (1) EP2943204B1 (enExample)
JP (1) JP6346904B2 (enExample)
CN (1) CN105101970B (enExample)
ES (1) ES2730013T3 (enExample)
WO (1) WO2014110442A1 (enExample)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2599791C2 (ru) 2010-08-10 2016-10-20 Ремпекс Фармасьютикэлз, Инч. Циклические бороновые кислотно-эфирные производные и их использование в терапии
WO2013033461A1 (en) 2011-08-31 2013-03-07 Rempex Pharmaceuticals, Inc. Heterocyclic boronic acid ester derivatives and therapeutic uses thereof
US10561675B2 (en) 2012-06-06 2020-02-18 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
WO2014089365A1 (en) * 2012-12-07 2014-06-12 Venatorx Pharmaceuticals, Inc Beta-lactamase inhibitors
WO2014107535A1 (en) * 2013-01-04 2014-07-10 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US9241947B2 (en) 2013-01-04 2016-01-26 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US9101638B2 (en) 2013-01-04 2015-08-11 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
MX2015008627A (es) 2013-01-04 2015-09-23 Rempex Pharmaceuticals Inc Derivados de acido boronico y usos terapeuticos de los mismos.
CN105101970B (zh) 2013-01-10 2018-11-20 维纳拓尔斯制药公司 β-内酰胺酶抑制剂
US9944658B2 (en) 2013-03-14 2018-04-17 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
UA121309C2 (uk) 2014-02-03 2020-05-12 Вітае Фармасьютікалс, Ллс Дигідропіролопіридинові інгібітори ror-гамма
EP3140310B1 (en) 2014-05-05 2019-08-07 Rempex Pharmaceuticals, Inc. Synthesis of boronate salts and uses thereof
US9687497B1 (en) 2014-05-05 2017-06-27 Rempex Pharmaceuticals, Inc. Salts and polymorphs of cyclic boronic acid ester derivatives and therapeutic uses thereof
MX2016015093A (es) 2014-05-19 2017-03-27 Rempex Pharmaceuticals Inc Derivados de acido boronico y sus usos terapeuticos.
US20150361108A1 (en) * 2014-06-11 2015-12-17 VenatoRx Pharmaceuticals, Inc. Orally bioavailable beta-lactamase inhibitors
KR20220065084A (ko) * 2014-06-11 2022-05-19 베나토알엑스 파마슈티컬스, 인크. 베타-락타마제 억제제
US9511142B2 (en) 2014-06-11 2016-12-06 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
KR20170024087A (ko) 2014-07-01 2017-03-06 렘펙스 파머수티클스 인코퍼레이티드 보론산 유도체 및 그의 치료적 용도
LT6177B (lt) 2014-10-10 2015-07-27 Uab "Biocentras" Fermentų kompleksų išskyrimas iš steptomyces gougerotii 101, daugiafermentinių biopreparatų ruošimas bei taikymas
US10662205B2 (en) 2014-11-18 2020-05-26 Qpex Biopharma, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
EP3233869B1 (en) 2014-12-19 2019-09-25 Rempex Pharmaceuticals, Inc. Apparatus and continuous flow process for production of boronic acid derivatives
US10183934B2 (en) 2015-02-02 2019-01-22 Forma Therapeutics, Inc. Bicyclic [4,6,0] hydroxamic acids as HDAC inhibitors
SG11201708622UA (en) 2015-02-02 2017-11-29 Forma Therapeutics Inc 3-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as hdac inhibitors
WO2016149393A1 (en) 2015-03-17 2016-09-22 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
EP3347008B1 (en) * 2015-09-11 2022-03-09 Venatorx Pharmaceuticals, Inc. Beta-lactamase inhibitors
MX385332B (es) 2015-11-20 2025-03-18 Vitae Pharmaceuticals Llc Moduladores de ror-gamma.
WO2017100537A1 (en) * 2015-12-10 2017-06-15 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
CN105801610B (zh) * 2016-04-19 2018-05-18 武汉维舜医药科技有限公司 新型广谱β-内酰胺酶抑制剂
WO2017218950A1 (en) 2016-06-17 2017-12-21 Forma Therapeutics, Inc. 2-spiro-5- and 6-hydroxamic acid indanes as hdac inhibitors
EP3478693B1 (en) 2016-06-30 2021-07-21 Qpex Biopharma, Inc. Boronic acid derivatives and therapeutic uses thereof
WO2018027062A1 (en) 2016-08-04 2018-02-08 VenatoRx Pharmaceuticals, Inc. Boron-containing compounds
JOP20190024A1 (ar) 2016-08-26 2019-02-19 Gilead Sciences Inc مركبات بيروليزين بها استبدال واستخداماتها
CA3207747A1 (en) * 2016-09-14 2018-03-22 Yufeng Jane Tseng Novel substituted benzimidazole derivatives as d-amino acid oxidase (daao) inhibitors
US10201518B2 (en) 2016-09-28 2019-02-12 The University Of Hong Kong Bismuth(III) compounds and methods thereof
US20190359589A1 (en) 2017-01-23 2019-11-28 Basf Se Fungicidal pyridine compounds
SG11201908181XA (en) 2017-03-06 2019-10-30 Venatorx Pharmaceuticals Inc Solid forms and combination compositions comprising a beta-lactamase inhibitor and uses thereof
WO2018199291A1 (ja) * 2017-04-28 2018-11-01 大日本住友製薬株式会社 ヘテロ環誘導体
EP3630782A4 (en) 2017-05-26 2021-03-03 Venatorx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
EP3630783A4 (en) 2017-05-26 2021-03-03 Venatorx Pharmaceuticals, Inc. PENICILLIN-BINDING PROTEIN INHIBITORS
CN111225914B (zh) 2017-07-24 2022-10-11 生命医药有限责任公司 RORγ的抑制剂
WO2019018975A1 (en) 2017-07-24 2019-01-31 Vitae Pharmaceuticals, Inc. INHIBITORS OF ROR GAMMA
CN107607572B (zh) * 2017-09-15 2019-12-03 山东大学齐鲁医院 一种用于离体细胞水溶性代谢物的二维核磁共振检测方法
CN111212843B (zh) 2017-10-11 2025-05-16 Qpex生物制药有限公司 硼酸衍生物及其合成
WO2019100106A1 (en) * 2017-11-24 2019-05-31 The University Of Sydney Antibacterial compounds and methods of use thereof
US11613549B2 (en) 2018-01-23 2023-03-28 Basf Se Bromination of pyridine derivatives
KR102526964B1 (ko) 2018-02-26 2023-04-28 길리애드 사이언시즈, 인코포레이티드 Hbv 복제 억제제로서의 치환된 피롤리진 화합물
JP7329260B2 (ja) 2018-04-20 2023-08-18 キューペックス バイオファーマ， インコーポレイテッド ボロン酸誘導体およびその治療的使用
CA3003032A1 (en) * 2018-04-27 2019-10-27 Nanostics Inc. Methods of diagnosing disease using microflow cytometry
JP7360132B2 (ja) 2018-04-27 2023-10-12 住友ファーマ株式会社 オキソ置換化合物
US12173018B2 (en) 2018-05-25 2024-12-24 VenatoRx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
TWI846759B (zh) * 2018-11-29 2024-07-01 美商維納拓爾斯製藥公司 包含β-內醯胺酶抑制劑的組合物及其用途
JP7550421B2 (ja) * 2019-10-25 2024-09-13 住友ファーマ株式会社 オキソ置換化合物からなる医薬
EP4049680A4 (en) 2019-10-25 2024-01-10 Sumitomo Pharma Co., Ltd. NEW SUBSTITUTED CONDENSED RING CONNECTION
TW202128718A (zh) * 2019-11-26 2021-08-01 美商維納拓爾斯製藥公司 青黴素結合蛋白抑制劑
CN111254091B (zh) * 2020-01-20 2022-04-19 浙江工业大学 一种嗜麦芽窄食单胞菌gyh及其在降解氯代烃类污染物中的应用
AU2021289665A1 (en) 2020-06-10 2022-12-15 Aligos Therapeutics, Inc. Anti-viral compounds for treating coronavirus, picornavirus, and norovirus infections
MX2022007854A (es) * 2021-06-23 2022-12-26 Yoda Pharmaceuticals Inc Derivados del benzimidazol para el tratamiento y/o la prevención de enfermedades y trastornos mediados por el nlrp3.
IL309732A (en) 2021-07-09 2024-02-01 Aligos Therapeutics Inc Antiviral compounds
WO2023043816A1 (en) 2021-09-17 2023-03-23 Aligos Therapeutics, Inc. Anti-viral compounds for treating coronavirus, picornavirus, and norovirus infections
WO2025119216A1 (zh) * 2023-12-04 2025-06-12 珠海联邦制药股份有限公司 硼酸类β-内酰胺酶抑制剂及其制备方法和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100292185A1 (en) * 2009-05-12 2010-11-18 Burns Christopher J Beta-lactamase inhibitors
CN101983203A (zh) * 2007-11-13 2011-03-02 诺瓦提斯国际药物有限公司 β-内酰胺酶抑制剂

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ177159A (en) 1974-04-20 1978-03-06 Beecham Group Ltd Clavulanic acid, salts, esters and preparation thereof from streptomyces clavuligerus: pharmaceutical compositions
BR0014073A (pt) 1999-09-17 2002-07-16 Abbott Gmbh & Co Kg Pirazolopirimidinas como agentes terapêuticos
US7271186B1 (en) 2002-12-09 2007-09-18 Northwestern University Nanomolar β-lactamase inhibitors
AU2004256841A1 (en) 2003-06-10 2005-01-20 Fulcrum Pharmaceuticals, Inc. Beta-lactamase inhibitors and methods of use thereof
SG10201600029PA (en) 2004-03-30 2016-02-26 Millennium Pharm Inc Synthesis of boronic ester and acid compounds
CN1965838A (zh) 2005-11-17 2007-05-23 李海超 含头孢匹胺和β－内酰胺酶抑制剂的药物组合物
ES2373461T3 (es) 2005-12-07 2012-02-03 Basilea Pharmaceutica Ag Antibióticos útiles de monobactama.
US20100120715A1 (en) 2007-11-13 2010-05-13 Burns Christopher J Beta-lactamase inhibitors
DK2231667T3 (da) 2008-01-18 2013-12-16 Merck Sharp & Dohme Beta-lactamase-hæmmere
MX2012001156A (es) 2009-07-28 2012-05-08 Anacor Pharmaceuticals Inc Moleculas que contienen boro trisustituidas.
RU2599791C2 (ru) 2010-08-10 2016-10-20 Ремпекс Фармасьютикэлз, Инч. Циклические бороновые кислотно-эфирные производные и их использование в терапии
KR101738210B1 (ko) 2011-07-26 2017-05-19 욱크하르트 리미티드 베타-락탐계 항생제, 술박탐 및 베타―락타마아제 저해제를 포함하는 약학 조성물
WO2013053372A1 (en) 2011-10-13 2013-04-18 Therabor Pharmaceuticals Boronic acid inhibitors of beta-lactamases
MX352652B (es) 2011-12-22 2017-12-04 Ares Trading Sa Inhibidores de inmunoproteasoma selectivos de derivados del acido alfa-amino boronico.
EP2814483A2 (en) 2012-02-15 2014-12-24 Rempex Pharmaceuticals, Inc. Methods of treating bacterial infections
CN104822689B (zh) 2012-12-03 2016-11-02 弗·哈夫曼-拉罗切有限公司 取代的三唑硼酸化合物
WO2014089365A1 (en) 2012-12-07 2014-06-12 Venatorx Pharmaceuticals, Inc Beta-lactamase inhibitors
MX2015008627A (es) 2013-01-04 2015-09-23 Rempex Pharmaceuticals Inc Derivados de acido boronico y usos terapeuticos de los mismos.
WO2014107535A1 (en) 2013-01-04 2014-07-10 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US9101638B2 (en) * 2013-01-04 2015-08-11 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
CN105101970B (zh) 2013-01-10 2018-11-20 维纳拓尔斯制药公司 β-内酰胺酶抑制剂
US9944658B2 (en) 2013-03-14 2018-04-17 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
US9938291B2 (en) 2013-03-14 2018-04-10 The Trustess Of Columbia University In The City Of New York N-alkyl-2-phenoxyethanamines, their preparation and use
WO2015051101A1 (en) 2013-10-02 2015-04-09 Cubist Pharmaceuticals, Inc. B-lactamase inhibitor picoline salt
WO2015157618A1 (en) 2014-04-11 2015-10-15 The Texas A&M University System Novel inhibitors of the new delhi metallo beta lactamase (ndm-1)
MX2016015093A (es) * 2014-05-19 2017-03-27 Rempex Pharmaceuticals Inc Derivados de acido boronico y sus usos terapeuticos.
US20150361108A1 (en) * 2014-06-11 2015-12-17 VenatoRx Pharmaceuticals, Inc. Orally bioavailable beta-lactamase inhibitors
US9511142B2 (en) 2014-06-11 2016-12-06 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
KR20220065084A (ko) * 2014-06-11 2022-05-19 베나토알엑스 파마슈티컬스, 인크. 베타-락타마제 억제제
US20150361107A1 (en) 2014-06-11 2015-12-17 VenatoRx Pharmaceuticals, Inc. Orally bioavailable beta-lactamase inhibitors
KR20170024087A (ko) * 2014-07-01 2017-03-06 렘펙스 파머수티클스 인코퍼레이티드 보론산 유도체 및 그의 치료적 용도
EP3233869B1 (en) 2014-12-19 2019-09-25 Rempex Pharmaceuticals, Inc. Apparatus and continuous flow process for production of boronic acid derivatives
EP3347008B1 (en) * 2015-09-11 2022-03-09 Venatorx Pharmaceuticals, Inc. Beta-lactamase inhibitors
WO2017100537A1 (en) 2015-12-10 2017-06-15 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
CN105801610B (zh) 2016-04-19 2018-05-18 武汉维舜医药科技有限公司 新型广谱β-内酰胺酶抑制剂
EP3478693B1 (en) 2016-06-30 2021-07-21 Qpex Biopharma, Inc. Boronic acid derivatives and therapeutic uses thereof
WO2018027062A1 (en) 2016-08-04 2018-02-08 VenatoRx Pharmaceuticals, Inc. Boron-containing compounds
SG11201908181XA (en) 2017-03-06 2019-10-30 Venatorx Pharmaceuticals Inc Solid forms and combination compositions comprising a beta-lactamase inhibitor and uses thereof
EP3630782A4 (en) 2017-05-26 2021-03-03 Venatorx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
EP3630783A4 (en) 2017-05-26 2021-03-03 Venatorx Pharmaceuticals, Inc. PENICILLIN-BINDING PROTEIN INHIBITORS
US11247965B2 (en) 2017-12-11 2022-02-15 VenatoRx Pharmaceuticals, Inc. Hepatitis B capsid assembly modulators
US12173018B2 (en) 2018-05-25 2024-12-24 VenatoRx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
EP3802538A4 (en) 2018-05-30 2022-01-12 Venatorx Pharmaceuticals, Inc. BROAD-SPECTRUM CARBAPENEMS
SG11202012346YA (en) 2018-06-11 2021-01-28 Venatorx Pharmaceuticals Inc Hepatitis b capsid assembly modulators
WO2020056048A1 (en) 2018-09-12 2020-03-19 VenatoRx Pharmaceuticals, Inc. Combination compositions comprising a beta-lactamase inhibitor
TWI846759B (zh) 2018-11-29 2024-07-01 美商維納拓爾斯製藥公司 包含β-內醯胺酶抑制劑的組合物及其用途
JP2022529212A (ja) 2019-04-02 2022-06-20 ベナトルクス ファーマシューティカルズ，インク． 経口送達されるベータ－ラクタマーゼ阻害剤の固体形態およびその使用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101983203A (zh) * 2007-11-13 2011-03-02 诺瓦提斯国际药物有限公司 β-内酰胺酶抑制剂
US20100292185A1 (en) * 2009-05-12 2010-11-18 Burns Christopher J Beta-lactamase inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Design, synthesis, crystal structures and antimicrobial activity of sulfonamide boronic acids as β-lactamase inhibitors;Oliv Eidam, et al.;《J Med Chem.》;20101111;第53卷(第21期);7852–7863 *

Also Published As

Publication number Publication date
JP2016506419A (ja) 2016-03-03
US20160304539A1 (en) 2016-10-20
US20150224125A1 (en) 2015-08-13
WO2014110442A1 (en) 2014-07-17
US20140194386A1 (en) 2014-07-10
US9376454B2 (en) 2016-06-28
US9771382B2 (en) 2017-09-26
US10125152B2 (en) 2018-11-13
ES2730013T3 (es) 2019-11-07
US11414435B2 (en) 2022-08-16
JP6346904B2 (ja) 2018-06-20
US9040504B2 (en) 2015-05-26
US20200317698A1 (en) 2020-10-08
US20170342093A1 (en) 2017-11-30
HK1217446A1 (zh) 2017-01-13
EP2943204B1 (en) 2019-03-13
US20160016978A1 (en) 2016-01-21
EP2943204A4 (en) 2016-11-09
US9403850B2 (en) 2016-08-02
CN105101970A (zh) 2015-11-25
EP2943204A1 (en) 2015-11-18

Similar Documents

Publication Publication Date Title
CN105101970B (zh) β-内酰胺酶抑制剂
JP6403219B2 (ja) ベータ−ラクタマーゼ阻害剤
US10294248B2 (en) Beta-lactamase inhibitors
CN108472284A (zh) β-内酰胺酶抑制剂
JP2020111612A (ja) トリアゾロピリジン化合物、ならびにそのプロリル水酸化酵素阻害剤およびエリスロポエチン産生誘導剤としての作用
CN109988186A (zh) β-内酰胺酶抑制剂
US20170145037A1 (en) Orally bioavailable beta-lactamase inhibitors
CN107759602A (zh) 含有共轭联烯结构的化合物、其药物组合物和用途
JP2023513373A (ja) Ｐ２ｘ３修飾薬
CN108602795A (zh) 金属-β-内酰胺酶的抑制剂
CN110272416A (zh) 吡唑并[3,4-c]吡啶-7-胺衍生物及其制备方法和应用
HK1217446B (zh) β-内酰胺酶抑制剂
HK40010334A (en) Beta-lactamase inhibitors
HK1217334B (en) Beta-lactamase inhibitors

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1217446

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20181120

CF01 Termination of patent right due to non-payment of annual fee